“The V-Chip could make it possible to bring tests to the bedside, remote areas, and other types of point-of-care needs,” said Nanomedicine faculty member Lidong Qin, Ph.D., the project’s principal investigator. “V-Chip is accurate, cheap, and portable. It requires only a drop of a sample, not a vial of blood, and can do 50 different tests in one go.”
Similar assays are typically done using heavy, large, complex equipment such as mass spectrometers, or require fluoroscopy analysis, which must also be done in a lab.
The V-chip, short for “volumetric bar-chart chip,” on the other hand, can be carried around in a pocket. It is composed of two thin pieces of glass, about 3 in. by 2 in. In between are wells for four things: (1) hydrogen peroxide, (2) up to 50 different antibodies to specific proteins, DNA or RNA fragments, or lipids of interest, and the enzyme catalase, (3) serum or other sample, and (4) a dye — any dye will do. Initially, the wells are kept separate from each other. A shift in the glass plates brings the wells into contact, creating a contiguous, zig-zagged space from one end of the V-chip to the other.
As the substance of interest — say, insulin — binds to antibodies bound to the glass slide, catalase is made active and splits nearby hydrogen peroxide into water and oxygen gas. This approach is called ELISA, or enzyme-linked immunosorbent assay. The oxygen pushes the dye up the column. The more present insulin is, the more oxygen is created, and the farther dye is pushed up the slide. Tests show that distance is more or less proportional to the amount of substrate present, in this example, insulin. The end result is a visual bar chart. Easy to read and accurate, Qin says, though development continues.
“The sensitivity of the V-chip can be improved if narrower and longer bar channels are used,” Qin said. “Our next steps are to make the device more user friendly and be so simple to use, it barely needs instructions.”
A Nature video about the device can be viewed at: http://www.nature.com/ncomms/journal/v3/n12/full/ncomms2292.html
Qin is also a Weill Cornell Medical College assistant professor of cell and developmental biology.
Also contributing to the Nature Communications paper were Yujun Song, Ph.D., Yuanqing Zhang, Ph.D., Paul Bernard, and Youli Zu, M.D., Ph.D., of The Methodist Hospital, and James M. Reuben, Ph.D., Naoto Ueno, M.D., and Ralph Arlinghaus, Ph.D., of MD Anderson Cancer Center. This work was funded with grants from the Cancer Prevention Research Institute of Texas, the Emily Hermann Research Fund, and the Golfers Against Cancer Foundation.
To speak with Lidong Qin, please contact David Bricker, The Methodist Hospital System, at 832-667-5811 or email@example.com.